Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of risankizumab in Japanese adults with moderate to severe palmoplantar pustulosis
jRCT2080225259Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Palmoplantar Pustular Psoriasis (PPPP) comparing Risankizumab with Placebo (2 arms). Started Jul 2020; status: completed.
02
Drugs
risankizumab
03
Conditions
Palmoplantar Pustular Psoriasis (PPPP)
Beyond the preview
Go deeper on jRCT2080225259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225259.